美股新聞 標題聯播 · 近 24 小時 284 則 · 25 個來源 · 最新 9/20 06:32
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · LXRX近 30 天 4 則 · 第 1 / 1 頁
- Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
- Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
- Novo Nordisk (CPSE:NOVO B) Reaches LX9851 Obesity Drug Milestone
- Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
- Hypertrophic Cardiomyopathy Market Set for Transformation Over the Next Decade with the Emergence of Targeted Cardiac Therapies Beyond Conventional Beta-blockers, Calcium Channel Blockers, and Antiarrhythmic Agents | DelveInsight
- Why Lexicon Pharmaceuticals (LXRX) Is Up 6.9% After Q2 Revenue Collapse And New Shelf Filings
- Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highlights: Zynquista NDA ...
- Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
- Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
- Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
- Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。